<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542110</url>
  </required_header>
  <id_info>
    <org_study_id>ASAP-SVG, QR#32711/1</org_study_id>
    <nct_id>NCT03542110</nct_id>
  </id_info>
  <brief_title>The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial</brief_title>
  <acronym>ASAP-SVG</acronym>
  <official_title>Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Heart Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneapolis Heart Institute Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study
      evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by
      IVUS at baseline and following 78 weeks of treatment in subjects with at least one
      intermediate SVG lesion receiving optimal statin therapy. Subjects will be randomized 1:1
      into 2 treatment groups: alirocumab 150 mg subcutaneously every 2 weeks or placebo
      subcutaneously every 2 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 4, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nominal change in intermediate SVG lesion percent atheroma volume (PAV) from baseline to 78 weeks post randomization, as assessed by intravascular ultrasonography (IVUS).</measure>
    <time_frame>78 weeks</time_frame>
    <description>To evaluate the effect of alirocumab on the change in burden of saphenous vein graft (SVG) atherosclerosis as measured by percent atheroma volume (PAV) in patients with intermediate SVG lesions who are undergoing clinically-indicated coronary angiography and are receiving optimal statin therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nominal change in TAV and normalized TAV of an intermediate SVG lesion from baseline to 78 weeks</measure>
    <time_frame>78 weeks</time_frame>
    <description>evaluate the effect of alirocumab on the change in total and normalized total atheroma volume (TAV) of an intermediate SVG lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic failure of target SVG lesion from baseline to 78 weeks.</measure>
    <time_frame>78 weeks</time_frame>
    <description>To evaluate the effect of alirocumab on the incidence of angiographic failure of an intermediate target SVG lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of target SVG failure and major adverse cardiac events.</measure>
    <time_frame>Randomization to 80 weeks</time_frame>
    <description>To evaluate the effect of alirocumab on the incidence of target SVG failure (defined as the composite of death, myocardial infarction, and target lesion revascularization) and the incidence of major adverse cardiac events (MACE, defined as the composite of death, acute coronary syndrome, or coronary revascularization) during follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Saphenous Vein Graft Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Alirocumab 150 MG/ML subcutaneous injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alirocumab 150 mg subcutaneously every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo subcutaneous injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo subcutaneously every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab 150 MG/ML subcutaneous injection</intervention_name>
    <description>Single-dose, pre-filled, disposable, subcutaneous injection pen</description>
    <arm_group_label>Alirocumab 150 MG/ML subcutaneous injection</arm_group_label>
    <other_name>Praluent, Study Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo subcutaneous injection</intervention_name>
    <description>Single-dose, pre-filled, disposable, subcutaneous injection pen</description>
    <arm_group_label>Matching Placebo subcutaneous injection</arm_group_label>
    <other_name>Placebo, Study Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or greater.

          2. Willing and able to give informed consent. The patients must be able to comply with
             study procedures and follow-up.

          3. Undergoing clinically-indicated coronary and SVG angiography.

          4. Have at least one target saphenous vein graft with an intermediate SVG lesion (defined
             as a lesion with 30-60% angiographic diameter stenosis) amenable to examination with
             IVUS. The SVG should have no thrombus or ulceration and should not be considered
             responsible for the patient's clinical presentation and referral for angiography.

          5. Receiving optimal statin therapy defined as use of a high intensity statin
             (atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily), any statin therapy with
             achieved LDL-C level &lt;70mg/dL, or maximally-tolerated statin dose for patients who are
             statin intolerant statin.

        Exclusion Criteria:

          1. Positive pregnancy test or breast-feeding.

          2. Coexisting conditions that limit life expectancy to less than 18 months or that could
             affect a patient's compliance with the protocol.

          3. Estimated glomerular filtration rate (eGFR) &lt;30 ml/min/1.73m2.

          4. Severe peripheral arterial disease limiting vascular access.

          5. History of allergic reaction to iodine-based contrast agents that cannot be
             premedicated.

          6. Known hypersensitivity to alirocumab.

          7. Any prior use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanouil S Brilakis, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Minneapolis Heart Institute and Foundation/ Abbott Northwestern Hospital-Allina Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute/ Abbott North Western Hospital-Allina Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. J Am Coll Cardiol. 2000 Nov 15;36(6):1877-83.</citation>
    <PMID>11092659</PMID>
  </reference>
  <reference>
    <citation>DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. Natl Health Stat Report. 2008 Jul 30;(5):1-20.</citation>
    <PMID>18841653</PMID>
  </reference>
  <reference>
    <citation>Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2446-54.</citation>
    <PMID>16287955</PMID>
  </reference>
  <reference>
    <citation>Sabik JF 3rd. Understanding saphenous vein graft patency. Circulation. 2011 Jul 19;124(3):273-5. doi: 10.1161/CIRCULATIONAHA.111.039842.</citation>
    <PMID>21768550</PMID>
  </reference>
  <reference>
    <citation>Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH, Novitzky D; Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med. 2009 Nov 5;361(19):1827-37. doi: 10.1056/NEJMoa0902905.</citation>
    <PMID>19890125</PMID>
  </reference>
  <reference>
    <citation>Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W; VA Cooperative Study Group #207/297/364. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol. 2004 Dec 7;44(11):2149-56.</citation>
    <PMID>15582312</PMID>
  </reference>
  <reference>
    <citation>Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996 Sep;28(3):616-26.</citation>
    <PMID>8772748</PMID>
  </reference>
  <reference>
    <citation>Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv. 2009 Sep;2(9):855-60. doi: 10.1016/j.jcin.2009.06.014.</citation>
    <PMID>19778774</PMID>
  </reference>
  <reference>
    <citation>Brilakis ES, Lee M, Mehilli J, Marmagkiolis K, Rodes-Cabau J, Sachdeva R, Kotsia A, Christopoulos G, Rangan BV, Mohammed A, Banerjee S. Saphenous vein graft interventions. Curr Treat Options Cardiovasc Med. 2014 May;16(5):301. doi: 10.1007/s11936-014-0301-x.</citation>
    <PMID>24643432</PMID>
  </reference>
  <reference>
    <citation>Ellis SG, Brener SJ, DeLuca S, Tuzcu EM, Raymond RE, Whitlow PL, Topol EJ. Late myocardial ischemic events after saphenous vein graft intervention--importance of initially &quot;nonsignificant&quot; vein graft lesions. Am J Cardiol. 1997 Jun 1;79(11):1460-4.</citation>
    <PMID>9185633</PMID>
  </reference>
  <reference>
    <citation>Knatterud GL, White C, Geller NL, Campeau L, Forman SA, Domanski M, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Terrin ML, Rosenberg Y. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J. 2003 Feb;145(2):262-9.</citation>
    <PMID>12595843</PMID>
  </reference>
  <reference>
    <citation>Rodés-Cabau J, Facta A, Larose E, DeLarochellière R, Déry JP, Nguyen CM, Roy L, Proulx G, Gleeton O, Barbeau G, Noël B, Rouleau J, Boudreault JR, Bertrand OF. Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting. Am J Cardiol. 2007 Aug 15;100(4):640-5. Epub 2007 Jun 27.</citation>
    <PMID>17697821</PMID>
  </reference>
  <reference>
    <citation>Rodés-Cabau J, Bertrand OF, Larose E, Déry JP, Rinfret S, Bagur R, Proulx G, Nguyen CM, Côté M, Landcop MC, Boudreault JR, Rouleau J, Roy L, Gleeton O, Barbeau G, Noël B, Courtis J, Dagenais GR, Després JP, DeLarochellière R. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation. 2009 Nov 17;120(20):1978-86. doi: 10.1161/CIRCULATIONAHA.109.874057. Epub 2009 Nov 2.</citation>
    <PMID>19884468</PMID>
  </reference>
  <reference>
    <citation>Rodés-Cabau J, Bertrand OF, Larose E, Déry JP, Rinfret S, Urena M, Jerez M, Nombela-Franco L, Ribeiro HB, Allende R, Proulx G, Nguyen CM, Boudreault JR, Rouleau J, Roy L, Gleeton O, Barbeau G, Noël B, Côté M, Després JP, Dagenais GR, DeLarochellière R. Five-year follow-up of the plaque sealing with paclitaxel-eluting stents vs medical therapy for the treatment of intermediate nonobstructive saphenous vein graft lesions (VELETI) trial. Can J Cardiol. 2014 Jan;30(1):138-45. doi: 10.1016/j.cjca.2013.11.002. Epub 2013 Nov 6.</citation>
    <PMID>24365196</PMID>
  </reference>
  <reference>
    <citation>Kotsia AP, Rangan BV, Christopoulos G, Coleman A, Roesle M, Cipher D, de Lemos JA, McGuire DK, Packer M, Banerjee S, Brilakis ES. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. J Invasive Cardiol. 2015 Oct;27(10):E204-10.</citation>
    <PMID>26429851</PMID>
  </reference>
  <reference>
    <citation>Brilakis ES, Edson R, Bhatt DL, Goldman S, Holmes DR Jr, Rao SV, Shunk K, Rangan BV, Mavromatis K, Ramanathan K, Bavry AA, Garcia S, Latif F, Armstrong E, Jneid H, Conner TA, Wagner T, Karacsonyi J, Uyeda L, Ventura B, Alsleben A, Lu Y, Shih MC, Banerjee S; DIVA Trial Investigators. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet. 2018 May 19;391(10134):1997-2007. doi: 10.1016/S0140-6736(18)30801-8. Epub 2018 May 11.</citation>
    <PMID>29759512</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

